These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 26403651)

  • 1. Are we ready to change clinical practice after the 'soft and text' results?
    De Iuliis F; Lanza R; Scarpa S
    Future Oncol; 2015; 11(21):2857-60. PubMed ID: 26403651
    [No Abstract]   [Full Text] [Related]  

  • 2. Exemestane as first-line therapy in postmenopausal women with recurrent or metastatic breast cancer.
    Glück S
    Am J Clin Oncol; 2010 Jun; 33(3):314-9. PubMed ID: 19730353
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Switch to exemestane effective in early breast cancer.
    Gourd E
    Lancet Oncol; 2017 Jun; 18(6):e308. PubMed ID: 28506558
    [No Abstract]   [Full Text] [Related]  

  • 4. A review of exemestane in the management of breast cancer.
    Wong NS; Pritchard KI
    Expert Opin Pharmacother; 2005 Oct; 6(13):2353-63. PubMed ID: 16218894
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased estrogen sulfatase (STS) and 17beta-hydroxysteroid dehydrogenase type 1(17beta-HSD1) following neoadjuvant aromatase inhibitor therapy in breast cancer patients.
    Chanplakorn N; Chanplakorn P; Suzuki T; Ono K; Chan MS; Miki Y; Saji S; Ueno T; Toi M; Sasano H
    Breast Cancer Res Treat; 2010 Apr; 120(3):639-48. PubMed ID: 20151319
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Can exemestane improve adjuvant treatment for postmenopausal women with primary breast cancer?
    Hutchinson L
    Nat Clin Pract Oncol; 2004 Nov; 1(1):24-5. PubMed ID: 16264795
    [No Abstract]   [Full Text] [Related]  

  • 7. Adjuvant endocrine therapy in premenopausal women with breast cancer.
    González Martín A; de la Cruz S; Márquez R
    Breast Cancer Res Treat; 2010 Sep; 123 Suppl 1():43-7. PubMed ID: 20711666
    [No Abstract]   [Full Text] [Related]  

  • 8. Role of obesity on the efficacy of exemestane plus ovarian suppression in hormone receptor-positive premenopausal breast cancer.
    Şendur MA; Aksoy S; Akıncı MB; Ozdemir N; Dede DŞ; Altundag K; Zengin N; Yalçın B
    Future Oncol; 2015; 11(6):905-7. PubMed ID: 25760972
    [No Abstract]   [Full Text] [Related]  

  • 9. [New results of endocrine therapy of breast cancer (the role of Aromasin)].
    Semiglazov VF; Semiglazov VV; Klemtsel' AA; Barash NIu; Zhil'tsova EK; Bozhok AA; Mel'nikova OA; Paltuev RM; Dashian GA; Petrovskiĭ SG; Ivanov VG; Tonuzov EE; Berstein LM
    Vopr Onkol; 2004; 50(6):729-36. PubMed ID: 15755074
    [No Abstract]   [Full Text] [Related]  

  • 10. [ASCO 2006. Exemestane: a new drug for the adjuvant therapy of breast cancer].
    Perrone F
    Tumori; 2006; 92(4):suppl 1-9. PubMed ID: 17036536
    [No Abstract]   [Full Text] [Related]  

  • 11. Re: Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: meta-analysis.
    Bria E; Carlini P; Cognetti F; Terzoli E; Giannarelli D
    J Natl Cancer Inst; 2007 Jan; 99(2):176; author reply 176-7. PubMed ID: 17228003
    [No Abstract]   [Full Text] [Related]  

  • 12. Exemestane or tamoxifen?
    Atkins CD
    Lancet; 2007 May; 369(9573):1600; author reply 1600-1. PubMed ID: 17499597
    [No Abstract]   [Full Text] [Related]  

  • 13. The impact of adjuvant endocrine therapy on reducing the risk of distant metastases in hormone-responsive breast cancer.
    Herold CI; Blackwell KL
    Breast; 2008 Jan; 17 Suppl 1():S15-24. PubMed ID: 18279763
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparison of fulvestrant and the third-generation aromatase inhibitors in the second-line treatment of postmenopausal women with advanced breast cancer.
    Dodwell D; Vergote I
    Cancer Treat Rev; 2005 Jun; 31(4):274-82. PubMed ID: 15908126
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical evaluation of the use of exemestane as further hormonal therapy after nonsteroidal aromatase inhibitors in postmenopausal metastatic breast cancer patients.
    Carlini P; Michelotti A; Ferretti G; Ricci S; Giannarelli D; Pellegrini M; Cresti N; Di Cosimo S; Bria E; Papaldo P; Fabi A; Ruggeri EM; Milella M; Alimonti A; Salesi N; Cognetti F
    Cancer Invest; 2007 Mar; 25(2):102-5. PubMed ID: 17453821
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ovarian suppression for early breast cancer.
    Wilcken N; Stockler M
    Lancet; 2007 May; 369(9574):1668-70. PubMed ID: 17512837
    [No Abstract]   [Full Text] [Related]  

  • 17. Switching to aromatase inhibitors in early breast cancer.
    Boccardo F; Rubagotti A
    Lancet; 2007 Feb; 369(9561):533-5. PubMed ID: 17307082
    [No Abstract]   [Full Text] [Related]  

  • 18. [Aromatase inhibitors in the adjuvant therapy of breast carcinomas].
    Baumann ChK; Aebi S
    Ther Umsch; 2004 Jun; 61(6):359-64. PubMed ID: 15253160
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exemestane versus anastrozole as front-line endocrine therapy in postmenopausal patients with hormone receptor-positive, advanced breast cancer: final results from the Spanish Breast Cancer Group 2001-03 phase 2 randomized trial.
    Llombart-Cussac A; Ruiz A; Antón A; Barnadas A; Antolín S; Alés-Martínez JE; Alvarez I; Andrés R; García Saenz JA; Lao J; Carrasco E; Cámara C; Casas I; Martín M
    Cancer; 2012 Jan; 118(1):241-7. PubMed ID: 21717449
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Optimal adjuvant hormone therapy in postmenopausal women with hormone-sensitive mammary carcinoma: tamoxifen and the aromatase inhibitors anastrozole, exemestane and letrozole].
    van Nes JG; Seynaeve C; van de Velde CJ; Nortier JW
    Ned Tijdschr Geneeskd; 2006 Dec; 150(52):2863-9. PubMed ID: 17319217
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.